Quick Summary — INCR scores higher on quality with 6.0/10 vs IMCC's 5.4/10. IMCC trades at $0.29 while INCR trades at $1.03. Both analyzed daily using SEC EDGAR data across 13 institutional models.
INCR scores higher with a 6.0/10 quality rating vs IMCC's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
IMCC currently trades at $0.29 while INCR trades at $1.03. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily for both companies.
IMCC earns a Quality of Company score of 5.4/10 compared to INCR's 6.0/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
IMCC carries a SAFE value trap risk (12/100) while INCR shows SAFE risk (18/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both IMCC and INCR operate in Drug Manufacturers - Specialty & Generic, which has 79 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare IMCC vs INCR differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.